Last reviewed · How we verify
an antibody drug conjugate
an antibody drug conjugate is a Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It is currently in Phase 1 development. Also known as: ADC.
At a glance
| Generic name | an antibody drug conjugate |
|---|---|
| Also known as | ADC |
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer (PHASE1)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors (PHASE1)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (PHASE1, PHASE2)
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- an antibody drug conjugate CI brief — competitive landscape report
- an antibody drug conjugate updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about an antibody drug conjugate
What is an antibody drug conjugate?
an antibody drug conjugate is a Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Who makes an antibody drug conjugate?
an antibody drug conjugate is developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (see full CSPC ZhongQi Pharmaceutical Technology Co., Ltd. pipeline at /company/cspc-zhongqi-pharmaceutical-technology-co-ltd).
Is an antibody drug conjugate also known as anything else?
an antibody drug conjugate is also known as ADC.
What development phase is an antibody drug conjugate in?
an antibody drug conjugate is in Phase 1.
Related
- Manufacturer: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full pipeline
- Also known as: ADC
- Compare: an antibody drug conjugate vs similar drugs
- Pricing: an antibody drug conjugate cost, discount & access